Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of Machine Learning and Genomics to Predict Outcomes for Newly Diagnosed, Relapsed and Refractory Mature T-cell and NK/T-cell Lymphomas: a Global Study of the PETAL Consortium

NCT06067347 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06067347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of Machine Learning and Genomics to Predict Outcomes for Newly Diagnosed, Relapsed and Refractory Mature T-cell and NK/T-cell Lymphomas: a Global Study of the PETAL Consortium
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 5, 2024
Completion date
January 31, 2028
Enrollment
1,200 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell and nk-cell neoplasm